Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans

Aron Adkins, Rita Basu, Mai Persson, Betty Dicke, Pankaj Shah, Adrian Vella, W. Frederick Schwenk, Robert A. Rizza

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

To determine the mechanism(s) by which insulin inhibits endogenous glucose production (EGP) in nondiabetic humans, insulin was infused at rates of 0.25, 0.375, or 0.5 mU · kg-1 · min-1 and glucose was clamped at ∼5.5 mmol/l. EGP, gluconeogenesis, and uridine-diphosphoglucose (UDP)-glucose flux were measured using [3- 3H]glucose, deuterated water, and the acetaminophen glucuronide methods, respectively. An increase in insulin from ∼75 to ∼100 to ∼150 pmol/l (∼12.5 to ∼17 to ∼25 μU/ml) resulted in progressive (ANOVA; P < 0.02) suppression of EGP (13.1 ± 1.3 vs. 11.7 ± 1.03 vs. 6.4 ± 2.15 μmol · kg-1 · min-1) that was entirely due to a progressive decrease (ANOVA; P < 0.05) in the contribution of glycogenolysis to EGP (4.7 ± 1.7 vs. 3.4 ± 1.2 vs. -2.1 ± 1.3 μmol · kg-1 · min-1). In contrast, both the contribution of gluconeogenesis to EGP (8.4 ± 1.0 vs. 8.3 ± 1.1 vs. 8.5 ± 1.3 μmol · kg-1 · min-1) and UDP-glucose flux (5.0 ± 0.4 vs. 5.0 ± 0.3 vs. 4.0 ± 0.5 μmol · kg-1 · min-1) remained unchanged. The contribution of the direct (extracellular) pathway to UDP-glucose flux was minimal and constant during all insulin infusions. We conclude that higher insulin concentrations are required to suppress the contribution of gluconeogenesis of EGP than are required to suppress the contribution of glycogenolysis to EGP in healthy nondiabetic humans. Since suppression of glycogenolysis occurred without a decrease in UDP-glucose flux, this implies that insulin inhibits EGP, at least in part, by directing glucose-6-phosphate into glycogen rather than through the glucose-6-phosphatase pathway.

Original languageEnglish (US)
Pages (from-to)2213-2220
Number of pages8
JournalDiabetes
Volume52
Issue number9
DOIs
StatePublished - Sep 1 2003

Fingerprint

Glycogenolysis
Gluconeogenesis
Insulin
Glucose
Uridine Diphosphate Glucose
Analysis of Variance
Glucose-6-Phosphatase
Glucose-6-Phosphate
Glycogen

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans. / Adkins, Aron; Basu, Rita; Persson, Mai; Dicke, Betty; Shah, Pankaj; Vella, Adrian; Schwenk, W. Frederick; Rizza, Robert A.

In: Diabetes, Vol. 52, No. 9, 01.09.2003, p. 2213-2220.

Research output: Contribution to journalArticle

Adkins, A, Basu, R, Persson, M, Dicke, B, Shah, P, Vella, A, Schwenk, WF & Rizza, RA 2003, 'Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans', Diabetes, vol. 52, no. 9, pp. 2213-2220. https://doi.org/10.2337/diabetes.52.9.2213
Adkins, Aron ; Basu, Rita ; Persson, Mai ; Dicke, Betty ; Shah, Pankaj ; Vella, Adrian ; Schwenk, W. Frederick ; Rizza, Robert A. / Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans. In: Diabetes. 2003 ; Vol. 52, No. 9. pp. 2213-2220.
@article{33405961290c40f8b1e69694ca959a36,
title = "Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans",
abstract = "To determine the mechanism(s) by which insulin inhibits endogenous glucose production (EGP) in nondiabetic humans, insulin was infused at rates of 0.25, 0.375, or 0.5 mU · kg-1 · min-1 and glucose was clamped at ∼5.5 mmol/l. EGP, gluconeogenesis, and uridine-diphosphoglucose (UDP)-glucose flux were measured using [3- 3H]glucose, deuterated water, and the acetaminophen glucuronide methods, respectively. An increase in insulin from ∼75 to ∼100 to ∼150 pmol/l (∼12.5 to ∼17 to ∼25 μU/ml) resulted in progressive (ANOVA; P < 0.02) suppression of EGP (13.1 ± 1.3 vs. 11.7 ± 1.03 vs. 6.4 ± 2.15 μmol · kg-1 · min-1) that was entirely due to a progressive decrease (ANOVA; P < 0.05) in the contribution of glycogenolysis to EGP (4.7 ± 1.7 vs. 3.4 ± 1.2 vs. -2.1 ± 1.3 μmol · kg-1 · min-1). In contrast, both the contribution of gluconeogenesis to EGP (8.4 ± 1.0 vs. 8.3 ± 1.1 vs. 8.5 ± 1.3 μmol · kg-1 · min-1) and UDP-glucose flux (5.0 ± 0.4 vs. 5.0 ± 0.3 vs. 4.0 ± 0.5 μmol · kg-1 · min-1) remained unchanged. The contribution of the direct (extracellular) pathway to UDP-glucose flux was minimal and constant during all insulin infusions. We conclude that higher insulin concentrations are required to suppress the contribution of gluconeogenesis of EGP than are required to suppress the contribution of glycogenolysis to EGP in healthy nondiabetic humans. Since suppression of glycogenolysis occurred without a decrease in UDP-glucose flux, this implies that insulin inhibits EGP, at least in part, by directing glucose-6-phosphate into glycogen rather than through the glucose-6-phosphatase pathway.",
author = "Aron Adkins and Rita Basu and Mai Persson and Betty Dicke and Pankaj Shah and Adrian Vella and Schwenk, {W. Frederick} and Rizza, {Robert A.}",
year = "2003",
month = "9",
day = "1",
doi = "10.2337/diabetes.52.9.2213",
language = "English (US)",
volume = "52",
pages = "2213--2220",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans

AU - Adkins, Aron

AU - Basu, Rita

AU - Persson, Mai

AU - Dicke, Betty

AU - Shah, Pankaj

AU - Vella, Adrian

AU - Schwenk, W. Frederick

AU - Rizza, Robert A.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - To determine the mechanism(s) by which insulin inhibits endogenous glucose production (EGP) in nondiabetic humans, insulin was infused at rates of 0.25, 0.375, or 0.5 mU · kg-1 · min-1 and glucose was clamped at ∼5.5 mmol/l. EGP, gluconeogenesis, and uridine-diphosphoglucose (UDP)-glucose flux were measured using [3- 3H]glucose, deuterated water, and the acetaminophen glucuronide methods, respectively. An increase in insulin from ∼75 to ∼100 to ∼150 pmol/l (∼12.5 to ∼17 to ∼25 μU/ml) resulted in progressive (ANOVA; P < 0.02) suppression of EGP (13.1 ± 1.3 vs. 11.7 ± 1.03 vs. 6.4 ± 2.15 μmol · kg-1 · min-1) that was entirely due to a progressive decrease (ANOVA; P < 0.05) in the contribution of glycogenolysis to EGP (4.7 ± 1.7 vs. 3.4 ± 1.2 vs. -2.1 ± 1.3 μmol · kg-1 · min-1). In contrast, both the contribution of gluconeogenesis to EGP (8.4 ± 1.0 vs. 8.3 ± 1.1 vs. 8.5 ± 1.3 μmol · kg-1 · min-1) and UDP-glucose flux (5.0 ± 0.4 vs. 5.0 ± 0.3 vs. 4.0 ± 0.5 μmol · kg-1 · min-1) remained unchanged. The contribution of the direct (extracellular) pathway to UDP-glucose flux was minimal and constant during all insulin infusions. We conclude that higher insulin concentrations are required to suppress the contribution of gluconeogenesis of EGP than are required to suppress the contribution of glycogenolysis to EGP in healthy nondiabetic humans. Since suppression of glycogenolysis occurred without a decrease in UDP-glucose flux, this implies that insulin inhibits EGP, at least in part, by directing glucose-6-phosphate into glycogen rather than through the glucose-6-phosphatase pathway.

AB - To determine the mechanism(s) by which insulin inhibits endogenous glucose production (EGP) in nondiabetic humans, insulin was infused at rates of 0.25, 0.375, or 0.5 mU · kg-1 · min-1 and glucose was clamped at ∼5.5 mmol/l. EGP, gluconeogenesis, and uridine-diphosphoglucose (UDP)-glucose flux were measured using [3- 3H]glucose, deuterated water, and the acetaminophen glucuronide methods, respectively. An increase in insulin from ∼75 to ∼100 to ∼150 pmol/l (∼12.5 to ∼17 to ∼25 μU/ml) resulted in progressive (ANOVA; P < 0.02) suppression of EGP (13.1 ± 1.3 vs. 11.7 ± 1.03 vs. 6.4 ± 2.15 μmol · kg-1 · min-1) that was entirely due to a progressive decrease (ANOVA; P < 0.05) in the contribution of glycogenolysis to EGP (4.7 ± 1.7 vs. 3.4 ± 1.2 vs. -2.1 ± 1.3 μmol · kg-1 · min-1). In contrast, both the contribution of gluconeogenesis to EGP (8.4 ± 1.0 vs. 8.3 ± 1.1 vs. 8.5 ± 1.3 μmol · kg-1 · min-1) and UDP-glucose flux (5.0 ± 0.4 vs. 5.0 ± 0.3 vs. 4.0 ± 0.5 μmol · kg-1 · min-1) remained unchanged. The contribution of the direct (extracellular) pathway to UDP-glucose flux was minimal and constant during all insulin infusions. We conclude that higher insulin concentrations are required to suppress the contribution of gluconeogenesis of EGP than are required to suppress the contribution of glycogenolysis to EGP in healthy nondiabetic humans. Since suppression of glycogenolysis occurred without a decrease in UDP-glucose flux, this implies that insulin inhibits EGP, at least in part, by directing glucose-6-phosphate into glycogen rather than through the glucose-6-phosphatase pathway.

UR - http://www.scopus.com/inward/record.url?scp=0042320958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042320958&partnerID=8YFLogxK

U2 - 10.2337/diabetes.52.9.2213

DO - 10.2337/diabetes.52.9.2213

M3 - Article

C2 - 12941759

AN - SCOPUS:0042320958

VL - 52

SP - 2213

EP - 2220

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -